15 October 2019 | News
Admedus has sold the distribution rights to its CardioCel® and VascuCel® product range for $A36.2 million (including all earnouts) to LeMaitre Vascular Inc.
image credit- istock.com
Australia based Admedus Limited announces the sale of its CardioCel® and VascuCel® patch business to U.S based LeMaitre Vascular Inc., for up to $A36.2M ($A22.8M upfront) in cash payments to Admedus.
These products originated from the Company's proprietary, regenerative bio-scaffold platform technology, being used to address multiple cardiovascular procedures and repairs. LeMaitre is a global provider of implants and devices for the treatment of peripheral vascular diseases.
The CardioCel® product range is the only one to have achieved ten years without calcification or degradation in man - a significant benefit to patients otherwise forced to undergo recurrent operations. Surgeons use CardioCel® products to treat congenital heart defects, vessel and cardiovascular repairs, and peripheral vascular reconstruction. VascuCel® is used as a patch in great vessel repair, peripheral vascular reconstruction and suture line buttressing.
Under the agreement terms, Admedus receives $A22.8M upfront followed by deferred payments of $A1M each at 12 months and at 36 months. Additionally, the Company may receive up to $A11.4M in earn-out payments as follows:
Admedus retains manufacturing rights for up to three years and will continue manufacturing CardioCel® and VascuCel® at its Malaga facility in Western Australia for LeMaitre. The manufacturing agreement ensures Admedus a 20% margin over cost.
Admedus retains sole-control on all intellectual property for the underlying ADAPT® technology platform/process, including its breakthrough TAVR device and single-piece 3D aortic valve.